Illumina Backed By Advisory Firm In Roche Proxy Fight
The proxy advisory firm said in a Friday report that Roche's offer undervalues the company and that the California company's shareholders should keep in place the current board of directors and not vote for the independent nominees of the Swiss research health care company.
Roche blasted the ISS recommendation...
Already a subscriber? Click here to login